Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1654 • ACR Convergence 2025
A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-Driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts
Meena Afroze Shanta¹ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University, Spokane, WA
Background/Purpose: Chronic synovitis is a hallmark of juvenile idiopathic arthritis (JIA), and synovial fibroblasts are major perpetrators of inflammation and tissue destruction. Thus, we tested…
Abstract Number: 2029 • ACR Convergence 2025
Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis
Francina salabert-Carreras¹, Raquel Ugena-García², Cristina Rocamora-Gisbert³, Cristina Calomarde-Gómez², Clara Churtichaga Domenech¹, Judith Vidal ripoll¹, LOURDES MATEO SORIA⁴, Laia Gifre-Sala¹, Maria Aparicio³, Susana Holgado⁵, Águeda Prior Español¹, Anne Riveros frutos³, Ivette Casafont-Solé², Eva Forcadell Pirretas¹, Anna Pujol Manresa¹, Judit Font-Urgelles², Melania Martínez-Morillo¹ and Annika Nack³, ¹Hospital Germans Trias i Pujol, Barcelona, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴HOSPITAL GERMANS TRIAS I PUJOL, BADALONA, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Up to one-third of patients experience disease flares in adulthood, with…
Abstract Number: 0401 • ACR Convergence 2025
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Daniel Lovell¹, Nicolino Ruperto², Jennifer Huggins³, Ekaterina Alexeeva⁴, Colleen Correll⁵, John Bohnsack⁶, Stacey Tarvin⁷, Gabriele Simonini⁸, Thomas Griffin⁹, Andrew Zeft¹⁰, Gerd Horneff¹¹, Pierre Quartier¹², Iionka Orban¹³, Heather Walters¹⁴, Valda Stanevica¹⁵, Julisa Patel¹⁶, Adam M Huber¹⁷, Margalit Rosenkranz¹⁸, Daniel Kingsbury¹⁹, Rosie Scuccimarri²⁰, Gabriel Vega Cornejo²¹, Joost Swart²², Robert Carroll²³, Hermine Brunner¹, Tina Sherrard²⁴, Chiara Pallotti²⁵, Clara Malattia²⁶ and Alberto Martini²⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Università degli Studi Milano-Bicocca, Milan, Italy, ³Cincinnati Children's Medical Center, Cincinnati, OH, ⁴National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Utah, Salt Lake City, UT, ⁷Riley Hospital for Children at Indiana University, Indianapolis, IN, ⁸Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ⁹Atrium Health Levine Children’s Hospital, Charlotte, NC, ¹⁰Cleveland Clinic, Cleveland, OH, ¹¹Asklepios Klinik, Hamburg, Germany, ¹²Hôpital Necker-Enfants Malades, Paris, France, ¹³Department of Rheumatology and Clinical Immunology of Semmelweis University, Budapest, Hungary, ¹⁴Northwell, New Hyde Park, NY, ¹⁵Riga Stradiņš University, Riga, Latvia, ¹⁶Children’s Hospital of Georgia, Augusta University, Augusta, GA, ¹⁷IWK Grace Health Centre, Halifax, NS, Canada, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ²⁰McGill University Health Centre, Montreal, QC, Canada, ²¹Clinica de reumatología Guadalajara, Guadalajara, Jalisco, Mexico, ²²Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²³Bristol Myers Squibb, London, United Kingdom, ²⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²⁵Istituto G. Gaslini, Servizio di Sperimentazioni Cliniche Pediatriche, Genova, Italy, ²⁶Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…
Abstract Number: 0420 • ACR Convergence 2025
Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial
Pernille Büyesen¹, Anna-Birgitte Aga¹, Vibke Lilleby¹, Maiju Pesonen¹, Marite Rygg², Ellen Nordal³, Bjørn Barstad⁴, Karin Tylleskär⁵, Helga Sanner¹, Siri Hetlevik¹, Nina Martine Sande¹, Inge Christoffer Olsen¹, Siri Lillegraven⁶, Espen Haavardsholm⁷, Athimalaipet Ramanan⁸, Oyvind Molberg⁹ and Berit Flatø¹, ¹Oslo University Hospital, Oslo, Norway, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ³University Hospital of North Norway, Tromsø, Nepal, ⁴Stavanger University Hospital, Stavanger, Norway, ⁵Haukeland University Hospital, Bergen, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Bristol Royal Hosp for Children, Bristol, United Kingdom, ⁹Oslo University Hospital, Oslo, Nepal
Background/Purpose: Modern therapies have improved outcomes in patients with JIA, but up to 60% of patients treated with TNF-α inhibitors (TNFi) have persisting disease activity…
Abstract Number: 1704 • ACR Convergence 2025
Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
William Soulsby¹, John Boscardin², Daniel Horton³, Andrea Knight⁴, Karine Toupin-April⁵ and Emily von Scheven², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Social determinants of health (SDOH) operate across individual, family, and community levels. We previously demonstrated that cumulative social disadvantage, comprised of individual and family-level…
Abstract Number: 2130 • ACR Convergence 2025
Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
Ashwini Batchu Prithvi, Chaitra Govardhan, Bushra Aladaileh and Athimalaipet V Ramanan, Bristol Royal Hospital for Children, Bristol, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a chronic disease that results in significant morbidity and mortality in children1. Improved understanding of the pathophysiology of…
Abstract Number: 0403 • ACR Convergence 2025
IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya¹, Elena Zholobova², Elizaveta Krekhova³, Valeria Matkava⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁶, Mikhail Kostik⁷ and Irina Nikishina⁴, ¹National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, ³National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health, Moscow, Russia, ⁴V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁵H.Turner National Medical Research Center for Childrens Orthopaedics and Trauma Surgery, Saint-Petersburg, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 (IL-6) inhibitor. IL-6 is an attractive target for the treatment of pJIA. The aim of the study was…
Abstract Number: 0422 • ACR Convergence 2025
Clinical Outcomes of Ultrasound Guidance for Corticosteroid Injections of the Ankle and Midfoot Joints and Tendon Sheaths in Children with Juvenile Idiopathic Arthritis
Rina Ferguson¹, Xing Wang², Erin Balay-Dustrude³, Ramesh Iyer³, Natalie Rosenwasser¹, Susan Shenoi⁴ and Yongdong (Dan) Zhao⁵, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Hospital, Seattle, ³University of Washington, Seattle, WA, ⁴Seattle Children's Hospital and Research Center, Mercer Island, WA, ⁵Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Intra-articular corticosteroid injections (IACI) are used to treat active ankle or midfoot inflammation in juvenile idiopathic arthritis (JIA). Ultrasound (US) can help identify the…
Abstract Number: 1809 • ACR Convergence 2025
Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
Andrew Zeft¹, Sirada Panupattanapong², Laura Nedorezov³, Sumit Bhutada³ and Suneel Apte³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic disease marked by persistent synovial inflammation, often leading to structural joint damage. While numerous proteases produced by…
Abstract Number: 2132 • ACR Convergence 2025
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Ayah Eltoum¹, Eileen Rife², Livie Timmerman³, Emily Smitherman⁴, Melissa Mannion⁴ and John Bridges⁵, ¹University of Alabama at Birmingham, Hoover, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL
Background/Purpose: The transition from pediatric to adult-oriented rheumatology care is a critical period for young adults with childhood-onset rheumatic diseases. The Bridge to Adult Care…
Abstract Number: 0404 • ACR Convergence 2025
Disease Extension in Children with Limited Juvenile Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Eveline Wu¹, Stephen Balevic², Angel Marks³, Manjushri Bhapkar⁴, Baoshan Zhang³, Alex Fist⁴, Melanie Kohlheim⁵, Vincent Del Gaizo⁶, Laine Thomas³ and Laura Schanberg⁷, ¹UNC Chapel Hill, Chapel Hill, NC, ²Department of Pediatrics, Duke University, Durham, ³Department of Biostatistics & Bioinformatics, Duke University, Durham, ⁴Duke Clinical Research Institute, Duke University, Durham, ⁵CARRA, Granville, OH, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Duke University Medical Center, DURHAM, NC
Background/Purpose: For children with limited juvenile idiopathic arthritis (JIA), defined as ≤4 affected joints and without uveitis, psoriasis, or sacroiliitis at presentation, it is unknown…
Abstract Number: 0424 • ACR Convergence 2025
Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India
Sreelekha Kambhampati¹, keerthi vardhan yerram², Kavitha Meesala¹, Phani Kumar Devarasetti² and Liza rajasekhar³, ¹Nizams institute of medical sciences, hyderabad, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic arthritis in children, but its diagnosis is often challenging due to overlapping symptoms with other…
Abstract Number: 1810 • ACR Convergence 2025
Destabilized Treg Cells Predominant in Severe Forms of Juvenile Idiopathic Arthritis
Ki Pui Lam¹, Claudia Harris², Jennifer Cheng³, Lwiza AitDowd⁴, Maryam Ashoor⁵, Ahmad Bakhsh³, Carrie Bryant³, Siobhan Case⁶, Mia Chandler³, Joyce Chang³, Ezra Cohen⁷, Fatma Dedeoglu³, Olha Halyabar⁸, Jonathan Hausmann⁹, Melissa Hazen³, Sonia Iosim¹⁰, Liyoung Kim¹¹, Jeffrey Lo³, Mindy Lo³, Emma Materne³, Esra Meidan¹², Megan Perron¹³, Helene Powers¹⁰, Mary Beth Son³, Holly Wobma³, Margaret Chang³, Pui Lee¹⁴, Peter Nigrovic¹¹ and Lauren Henderson¹⁵, ¹Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Childrens Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Brookline, MA, ⁶UpToDate, Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁷Bmc, NEEDHAM, MA, ⁸Children's Hospital/Boston Medical Center, Newton, MA, ⁹Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ¹⁰Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ¹¹Boston Children's Hospital, Brookline, MA, ¹²Boston Children's Hospital, Somerville, MA, ¹³Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Natick, MA, ¹⁴Boston Children's Hospital, Newton, MA, ¹⁵Boston Children's Hospital, Watertown, MA
Background/Purpose: T peripheral helper (Tph) cells stimulate excessive B cell responses in the joints of patients with autoantibody-positive arthritis, including seropositive RA in adults and…
Abstract Number: 2134 • ACR Convergence 2025
Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
Eileen Rife¹, Lexi Auld², Guihua Zhai³, Esraa Eloseily⁴, Grant Schulert⁵ and Yukiko Kimura⁶, ¹University of Alabama at Birmingham, birmingham, AL, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³UAB, Birmingham, ⁴UT Southwestern Children's Medical Center, Dallas, TX, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Children with Systemic Juvenile Idiopathic Arthritis (SJIA) who develop lung disease (LD) are at significantly increased risk of serious complications and even death. Early…
Abstract Number: L09 • ACR Convergence 2024
Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine Brunner¹, Caifeng Li², Kogie Chinniah³, Yosef Uziel⁴, Olga Synoverska⁵, Sujata Sawhney⁶, Inmaculada Calvo Penades⁷, Ingrid Clara Louw⁸, Meiping Lu⁹, Pooja Nikunj Patel¹⁰, Pamela F. Weiss¹¹, Cheng Chang¹², Ivana Vranic¹³, Shixue Liu¹⁴, Annette Diehl¹⁵, Jose L. Rivas¹⁶, Carol A. Connell¹⁷, Gary G. Koch¹⁸, Alberto Martini¹⁹, Daniel J. Lovell¹, Nicolino Ruperto²⁰ and the PRINTO and PRCSG investigators, ¹Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, ²Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, ³Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, ⁴Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, ⁵Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, ⁶Sir Ganga Ram Hospital, New Delhi, India, ⁷Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁸Panorama Medical Centre, Cape Town, South Africa, ⁹Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ¹⁰Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³Pfizer Ltd, Tadworth, United Kingdom, ¹⁴Pfizer Inc, Shanghai, China, ¹⁵Pfizer Inc, Collegeville, PA, ¹⁶Pfizer SLU, Madrid, Spain, ¹⁷Pfizer Inc, Groton, CT, ¹⁸University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹University of Genoa, Genoa, Italy, ²⁰Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy
Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…

« Previous Page
1
…
3
4
5
6
7
…
25
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].